{
    "Trade/Device Name(s)": [
        "VIDAS\u00ae Lyme IgM"
    ],
    "Submitter Information": "bioM\u00e9rieux SA",
    "510(k) Number": "K122979",
    "Predicate Device Reference 510(k) Number(s)": [
        "K081362"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "LSR"
    ],
    "Summary Letter Date": "May 6, 2013",
    "Summary Letter Received Date": "May 7, 2013",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3830"
    ],
    "Regulation Name(s)": [
        "Treponema pallidum treponemal test reagents"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "immunology"
    ],
    "Analyte(s)": [
        "IgM antibodies to Borrelia burgdorferi"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Plain tube",
        "Separation gel tube",
        "Sodium heparin tube",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "VIDAS family instruments"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked fluorescent assay (ELFA)",
        "Enzyme immunoassay (EIA)"
    ],
    "Methodologies": [
        "Enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for VIDAS Lyme IgM automated qualitative enzyme immunoassay for detecting IgM antibodies to Borrelia burgdorferi in human serum or plasma.",
    "Indications for Use Summary": "Automated qualitative enzyme immunoassay for presumptive detection of human IgM antibodies to Borrelia burgdorferi in serum or plasma from patients with a history and/or symptoms of infection; positive/equivocal results require confirmation with a Western Blot IgM assay.",
    "fda_folder": "Microbiology"
}